Trenton, June 19, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, issued the following statement concerning this week’s announcement of the Food and Drug Administration (FDA)’s Commissioner’s National Priority Voucher (CNPV) program for accelerating FDA approvals:
“Researching and discovering a new treatment or cure can take a decade or longer and cost billions of dollars. The most important priority is to ensure a product is safe and effective for patients. Researchers, clinicians and government regulatory agencies work collaboratively to review all available data – from lab bench to clinical trials to post-market reviews – to confirm product safety and efficacy.”
Buteas continued, “Anything that can shorten a review period without compromising safety and efficacy means patients will benefit from new discoveries even sooner. Our companies will continue to partner with FDA and other stakeholders to deliver our life-saving treatments and cures to patients as quickly and as safely as possible.”